6-Methyltryptamine (6-Me-T or 6-methyl-T; developmental code name PAL-522) is a serotonin receptor modulator and monoamine releasing agent of the tryptamine family. It is the 6-methyl derivative of tryptamine.
The drug acts as a potent full agonist of the serotonin 5-HT2A receptor, with an of 75.3nM and an of 110%. It is about 10-fold less potent as a serotonin 5-HT2A receptor agonist than tryptamine itself. In addition to its serotonin 5-HT2A receptor agonism, 6-methyltryptamine is a serotonin–dopamine releasing agent (SDRA), with values for induction of monoamine release of 51.6nM for serotonin, 353nM for dopamine, and >10,000nM for norepinephrine in rat brain synaptosomes. It shows extremely weak affinity for the dizocilpine (MK-801) site of the NMDA receptor ( = 175,000–260,000nM).
Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.
The chemical synthesis of 6-methyltryptamine has been described.
6-Methyltryptamine was first described in the scientific literature by 1965. Its pharmacology was subsequently assessed in greater detail in 2014.
See also Substituted tryptamine 6-Methyl-DMT 6-Methyl-5-MeO-DMT 6-Methoxytryptamine 6-Hydroxytryptamine 6-Fluorotryptamine 6-Bromotryptamine
References
External links 6-Methyl-T - Isomer Design